SEC 13F Intelligence

Boundary Creek Advisors LP / SLS

Boundary Creek Advisors LP’s Sellas Life Sciences Group I Position

Does Boundary Creek Advisors LP own Sellas Life Sciences Group I (SLS)? Not currently — the last reported position was 4.98M shares worth $23M in Q2 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$23M
Q2 2025
Shares
4.98M
% of Portfolio
+4.99%
Quarters Held
5
position exited

Position History SLS

Reported value by quarter
Q2 ’24: $17MQ2 ’24Q3 ’24: $19MQ3 ’24Q4 ’24: $22MQ4 ’24Q1 ’25: $25MQ1 ’25Q2 ’25: $23MQ2 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q2 20254.98M$23M+4.99%
Q1 20257.41M$25M+6.64%
Q4 20247.19M$22M+1.46%
Q3 20247.23M$19M+1.45%
Q2 20246.22M$17M+1.59%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Boundary Creek Advisors LP’s full portfolio or all institutional holders of SLS.